Fierce Biotech Video Interview: “GATC Health unveils AI-powered risk tool to predict clinical trial success” 

GATC Health’s Chief Business Officer Tyrone Lam discusses importance of the company’s Derisq product in driving capital allocation decisions.

Fierce Biotech—a leading publication trusted by life science executives and investors—has spotlighted GATC Health in a new video interview titled, “GATC Health unveils AI-powered risk tool to predict clinical trial success.”

In the interview, GATC Health’s Chief Business Officer Tyrone Lam discusses the significance of the company’s innovative Derisq™ AI Report and its role in transforming how capital allocation decisions are made in drug development.

This high-profile interview marks an important moment following the official launch of Derisq during Fierce Biotech Week, where GATC Health joined other industry leaders driving the future of biotechnology. The discussion explores how GATC Health’s AI-powered risk model is shaping the next generation of decision-making tools for biopharma.​

Watch the video interview.

Derisq leverages proprietary AI technology to deliver standardized risk reports for biotech assets—empowering stakeholders to make informed, data-driven decisions earlier in the development process. This innovation meets a crucial industry need by improving capital efficiency, enabling go/no-go decisions, and mitigating the high rates of clinical trial failure.​

GATC Health invites the biotech and investment community to view the Fierce Bio interview and discover how Derisq advances risk management and accelerates progress in life sciences.

About GATC Health

GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.